Conference Coverage
about 5 hours ago
NeurologyLive® Year in Review 2025: Conference Coverage RecapLatest News
Dec 29, 2025 | News
NeurologyLive® Year in Review 2025: Most Impactful FDA Decisions
NeurologyLive® Year in Review 2025: Conference Coverage Recap
Dec 29, 2025
Phase 3 REVITALYZ Trial of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia Finishes Enrollment
Dec 28, 2025
NeurologyLive® Brain Games: December 28, 2025
Dec 28, 2025
Wnt/β-catenin in Multiple Sclerosis: A Nuanced Approach to Remyelination
Dec 27, 2025
Advertisement
Shorts
Media-Driven Misconceptions of Narcolepsy
18 days ago
by
Julie Flygare, JD(+1 more)
0:30
Barriers to Early Diagnosis and Access to Care in MS
a month ago
by
Ethel Ciampi, MD, MSc(+1 more)
1:30
Collaboration Within the ALS Community
2 months ago
by
Jinsy A. Andrews, MD, MSc(+1 more)
1:30
Safety Considerations for Kygevvi in Tk2d
2 months ago
by
Fabian Somers, PhD(+1 more)
1:30
Data Backing First Treatment for Tk2d
2 months ago
by
Fabian Somers, PhD(+1 more)
1:30
Training the Next Neuromuscular Specialists
2 months ago
by
John Norbury, MD(+1 more)
1:15
Evolving Landscape of Myasthenia Gravis Treatment
2 months ago
by
Leila Darki, MD(+1 more)
1:05
Aerobic Exercise and Promoting Remyelination in MS
2 months ago
by
Lindsey Wooliscroft, MD, MS(+1 more)
1:12
MDS 2025: Learning From Progress in Other Disease States
3 months ago
by
Lorraine Kalia, MD, PhD(+1 more)
1:16
MDS 2025: Biologically Defining Parkinson Disease
3 months ago
by
Tanya Simuni, MD, FAAN(+1 more)
Coverage of AANEM 2025
Get direct access to interviews with experts, straight from the conference floor in San Francisco, as well as the latest data and clinical news updates.
Mind Moments Podcast
Mind Moments® is a biweekly podcast from NeurologyLive that brings you exclusive interviews with expert neurologists and clinicians.
DAMM Good Sleep
Check out DAMM Good Sleep × NeurologyLive for neurology-focused sleep content to allow any neurology stakeholder to use sleep as the diagnostic, prognostic, and therapeutic neurology tool it should be.
NeuroVoices
NeuroVoices is NeurologyLive's series of in-depth, exclusive Q&A conversations with a variety of experts in the care and management of patients with neurologic diseases about topics in clinical care and therapeutic development.
Gold Standard Centers
Gold Standard Centers is our deep dive feature series on examples of institutional success in neurologic medicine, highlighting the centers that are leading the way in care.
Videos
Podcasts
Advertisement
All News
Advertisement
Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.
As part of NeurologyLive®'s Year in Review 2025, we've compiled the most-listened episodes this year of our biweekly podcast, Mind Moments®.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Lindsay McCullough, MD. [LISTEN TIME: 14 minutes]
A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.
A trio of neurology experts discussed the clinical application of the 2025 updated multiple sclerosis diagnostic criteria, including imaging and biomarker tools, to support patient care.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.
The director of the Pediatric Epilepsy Center at UCSF reviewed recently presented interim phase 1/2 data for ETX101, a one-time AAV9 gene regulation therapy aiming to increase SCN1A expression in inhibitory interneurons in Dravet syndrome.
As part of NeurologyLive®'s Year in Review 2025, we've compiled some notable trials that began in 2025.
Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.
Advertisement
Explore the evolving landscape of developmental and epileptic encephalopathies in adults, highlighting precision therapies and the need for accurate diagnoses.
Brain-Penetrant Molecule GT-02287 Demonstrates Reversal of Glucosylsphinogosine in Parkinson Disease
Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.
Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.
Here's some of what is coming soon to NeurologyLive® this week.
Here's some of what is coming soon to NeurologyLive® this week.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 3 REVITALYZ Trial of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia Finishes Enrollment
2
NeurologyLive® Year in Review 2025: Most Impactful FDA Decisions
3
Wnt/β-catenin in Multiple Sclerosis: A Nuanced Approach to Remyelination
4
Assessing Antisense Oligonucleotide Apazunersen in Pediatric Angelman Syndrome: The Aspire Study
5